Fluorine-containing pharmaceuticals, or fluoro-pharmaceuticals, have been widely used in drug development for over half a century, with approximately 20% of commercial drugs being fluoro-pharmaceuticals. This mini-review analyzes the prevalence and categorization of fluoro-pharmaceuticals based on their chemotype, therapeutic purpose, and presence of heterocycles or chirality. The database includes 340 fluoro-pharmaceuticals, from the first fluoro-pharmaceutical, Florinef, to those registered in 2019 and withdrawn drugs. The review highlights the structural motifs and promising trends in fluorine-based drug design. Fluoro-pharmaceuticals have shown significant success in various therapeutic areas, including antimicrobial, antitumor, and anti-inflammatory activities. They are often categorized into groups based on the type of fluoro-functional group, such as Ar–F, Het–F, and CF3. The most common fluoro-functional groups are monofluorinated moieties, followed by trifluoromethyl groups. The analysis also reveals that fluoro-pharmaceuticals with heterocyclic fragments are relatively rare, but their structural diversity is limited. Chirality is an important factor in drug development, as enantiomers can exhibit different biological activities. The review discusses the importance of chiral fluoropharmaceuticals, including the use of chiral fluorinated thalidomide to overcome racemization issues. Over 50% of marketed drugs are chiral compounds, and the review identifies 62 fluoropharmaceuticals with a fluorine or fluoro-functional group directly connected to a stereogenic carbon center. The review also highlights the potential of fluoro-pharmaceuticals in the future, particularly with advancements in fluorine-based drug discovery. The development of new synthetic methods for fluorinated heterocyclic compounds, including asymmetric reactions, could enhance the potential of fluorine-based drug discovery. The review concludes that the continuous success of fluoro-pharmaceuticals suggests that choosing fluoro-organic molecules could be a potential strategy to significantly minimize the risk of unsuccessful drug discovery attempts. The review also emphasizes the importance of further research to understand the effects of fluorine and fluorinated functional groups on target proteins and DNA.Fluorine-containing pharmaceuticals, or fluoro-pharmaceuticals, have been widely used in drug development for over half a century, with approximately 20% of commercial drugs being fluoro-pharmaceuticals. This mini-review analyzes the prevalence and categorization of fluoro-pharmaceuticals based on their chemotype, therapeutic purpose, and presence of heterocycles or chirality. The database includes 340 fluoro-pharmaceuticals, from the first fluoro-pharmaceutical, Florinef, to those registered in 2019 and withdrawn drugs. The review highlights the structural motifs and promising trends in fluorine-based drug design. Fluoro-pharmaceuticals have shown significant success in various therapeutic areas, including antimicrobial, antitumor, and anti-inflammatory activities. They are often categorized into groups based on the type of fluoro-functional group, such as Ar–F, Het–F, and CF3. The most common fluoro-functional groups are monofluorinated moieties, followed by trifluoromethyl groups. The analysis also reveals that fluoro-pharmaceuticals with heterocyclic fragments are relatively rare, but their structural diversity is limited. Chirality is an important factor in drug development, as enantiomers can exhibit different biological activities. The review discusses the importance of chiral fluoropharmaceuticals, including the use of chiral fluorinated thalidomide to overcome racemization issues. Over 50% of marketed drugs are chiral compounds, and the review identifies 62 fluoropharmaceuticals with a fluorine or fluoro-functional group directly connected to a stereogenic carbon center. The review also highlights the potential of fluoro-pharmaceuticals in the future, particularly with advancements in fluorine-based drug discovery. The development of new synthetic methods for fluorinated heterocyclic compounds, including asymmetric reactions, could enhance the potential of fluorine-based drug discovery. The review concludes that the continuous success of fluoro-pharmaceuticals suggests that choosing fluoro-organic molecules could be a potential strategy to significantly minimize the risk of unsuccessful drug discovery attempts. The review also emphasizes the importance of further research to understand the effects of fluorine and fluorinated functional groups on target proteins and DNA.